Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of three potency levels of V181 dengue quadrivalent vaccine in healthy adults
2020-004501-30Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2021
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TetraVax-DV in dengue fever (3 arms), sponsored by Merck & Co. Primary endpoint: Dengue virus-neutralizing antibody titers measured by virus reduction neutralization test. Started Dec 2021; status: completed.
02
Drugs
TetraVax-DV
03
Conditions
dengue fever
Beyond the preview
Go deeper on 2020-004501-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004501-30.